Regulatory and oversight concern around AI hallucinations is not centered only on intentional misuse, but on the introduction of unverifiable, unsupported, or fabricated information into regulated workflows. As organizations increasingly integrate generative AI into documentation, quality systems, pharmacovigilance, clinical operations, and regulatory activities, regulators, courts, and oversight bodies are beginning to examine whether existing governance structures are sufficient to maintain data integrity, traceability, and accountability.
The issue is not that AI systems occasionally produce incorrect outputs. In regulated environments, inaccuracies become consequential when they are incorporated into records, submissions, decisions, or processes that organizations are expected to validate and defend.
This is why hallucinations are increasingly being treated not simply as technical anomalies, but as governance and oversight concerns.
AI hallucinations occur when a generative AI system produces information that is fabricated, unsupported, distorted, or otherwise inaccurate while presenting the output with apparent confidence or authority. In regulated environments, the practical issue is not only that the output is wrong, but that it may appear complete, professional, and source-based when it has not actually been verified.
In practical terms, this may include:
The operational concern is that many of these outputs appear plausible enough to avoid immediate detection, particularly when users assume the system is authoritative.
This creates a significant challenge in regulated industries, where organizations remain responsible for the accuracy and integrity of the information used to support regulated activities.
The growing regulatory focus on hallucinations reflects a broader concern around foundational compliance principles that already exist across regulated frameworks, including:
From a regulatory perspective, hallucinations generally do not create entirely new compliance obligations. Rather, they create new ways for organizations to fail existing obligations around accuracy, review, documentation, data integrity, and accountability. They expose weaknesses in how organizations apply existing controls when AI systems are introduced into regulated environments.
For example, if AI-generated content is incorporated into a submission, quality document, or pharmacovigilance assessment without appropriate verification, the issue is unlikely to be viewed as a software problem alone. Regulators may instead view it as a failure of oversight, review procedures, data integrity controls, validation controls, or governance.
This distinction is becoming increasingly important as organizations expand AI usage into operationally significant areas.
Recent legal developments in Canada illustrate how quickly hallucinations are moving from theoretical concern to operational risk.
In Hussein v Canada, 2025 FC 1060, the Federal Court addressed submissions containing fabricated or misrepresented case law generated through AI-assisted legal research. In the related costs decision, Hussein v Canada, 2025 FC 1138, the Court ordered modest costs personally against counsel, reinforcing that AI-generated outputs must be disclosed where required and verified by humans before being relied upon. Subsequent Federal Court guidance reinforced that parties using AI-generated content may face sanctions or adverse consequences where appropriate disclosure or verification obligations are not met.
The significance of these decisions extends beyond the legal profession itself.
They signal a broader accountability principle that is directly relevant to regulated industries: organizations remain responsible for the integrity of AI-assisted outputs, regardless of whether inaccuracies originate from the user, the tool, or the workflow around the tool. That principle is directly relevant to regulated industries already using AI in:
Hallucinations are problematic in any context, but their impact becomes amplified in regulated environments because regulated systems depend heavily on documented evidence, reproducibility, and defensible decision-making.
Once inaccurate information enters a regulated workflow, it may influence downstream processes in ways that are difficult to isolate or reverse.
For example:
The regulatory implications may include:
The concern is not limited to whether a hallucination occurred. Regulators are increasingly focused on whether appropriate controls existed to detect and prevent the issue before the information was operationalized.
One of the clearest areas of alignment across emerging AI governance frameworks is the continued importance of human oversight.
Whether discussed in regulatory guidance, international AI governance frameworks, quality-system expectations, or court decisions, the underlying principle remains consistent: AI-assisted outputs must remain subject to qualified human review proportionate to the risk and intended use of the output. This expectation is often described through models such as:
Although terminology varies, the operational implication is similar across frameworks.
Organizations are expected to ensure that:
The issue is particularly important because generative AI systems are designed to generate statistically plausible outputs rather than independently verified conclusions.
As several guidance documents now emphasize, large language models predict language patterns—they do not assess factual truth in the way human reviewers are expected to.
One of the more important regulatory developments is the shift away from viewing hallucinations solely as isolated software errors.
Increasingly, hallucinations are being connected to broader governance concerns involving:
This aligns with broader trends emerging across regulatory guidance, court expectations, quality systems, and AI management frameworks, including:
The direction of travel is increasingly clear: organizations are expected to govern AI-enabled processes with the same rigor applied to other regulated operational systems.
| Regulatory Area | Hallucination Risk | Potential Compliance Concern |
| Regulatory Submissions | Fabricated citations or unsupported claims | Misleading or unsupported submissions |
| Clinical Trials | Incorrect endpoint interpretation or references | Trial integrity concerns |
| Pharmacovigilance | Incorrect case classification or narratives | Adverse event reporting deficiencies |
| Medical Devices | Inaccurate technical documentation | Safety and effectiveness concerns |
| Quality Systems | AI-generated SOPs, deviations, investigations, or CAPAs containing inaccuracies | Inspection findings |
| Labeling & Claims | Unsupported substantiation | Misbranding or false advertising |
| Internal Governance | Inaccurate summaries, meeting records, audit trails, or decision logs | Data integrity deficiencies |
Organizations should not assume that AI usage falls outside regulatory scrutiny simply because the technology is being used internally or informally.
Where AI influences regulated activities, regulators are increasingly likely to examine:
This is especially important because AI adoption is often occurring faster than formal policy development inside organizations themselves.
Many companies have already integrated generative AI into operational workflows without fully evaluating where hallucination risk intersects with existing compliance obligations. That gap matters because informal AI use can still create formal compliance risk once the output is copied into a controlled document, regulatory record, submission, investigation, assessment, or client-facing deliverable.
As oversight expectations continue to mature, organizations will increasingly need to demonstrate not only that AI improves efficiency, but that its use remains controlled, traceable, and defensible.
The broader regulatory trajectory suggests that AI governance will increasingly become integrated into existing compliance, quality, and risk management frameworks rather than treated as a standalone technology issue.
This includes growing emphasis on:
The practical objective is not to eliminate AI use. The objective is to prevent unsupported AI-generated content from becoming part of the regulated record without appropriate verification, documentation, and accountability.
Organizations that establish these controls early will likely be better positioned as AI-specific expectations continue to evolve across jurisdictions.
For organizations adopting generative AI in regulated workflows, the key question is not simply whether AI can improve efficiency. The more important question is whether the organization can demonstrate that AI-assisted outputs remain accurate, reviewed, traceable, and defensible.
Organizations should be asking:
These questions are increasingly central to responsible AI adoption. AI may improve speed and efficiency, but in regulated environments, efficiency only has value if the output remains accurate, controlled, and defensible.
At dicentra, we work at the intersection of regulatory affairs, quality systems, clinical strategy, and compliance governance—where AI is increasingly influencing regulated operations and decision-making.
As organizations integrate AI into regulatory, safety, quality, clinical, and operational workflows, the focus is shifting from whether AI can be used to whether its use is appropriately governed, verified, documented, and defensible within regulated environments. We support organizations by:
Our role is to help organizations move from informal AI adoption to controlled AI implementation. That means identifying where AI is being used, assessing the risk of those use cases, strengthening verification and documentation controls, and building governance frameworks that allow organizations to benefit from AI without compromising the integrity of regulated processes.
Contact dicentra for support with AI governance, compliance risk management, and regulated AI implementation.